Answers are grounded in this paper and cite their sources.
Exploratory evaluation shows candidate metabolites reduce inflammatory responses in psoriasis-like models, suggesting therapeutic benefits.
Psoriasis is a chronic inflammatory seronegative disease closely associated with ankylosing spondylitis and inflammatory bowel disease. This study aimed to investigate the anti-inflammatory effects of candidate metabolites, such as D-proline, L-iditol, and propionylcarnitine, identified in Clonorchis sinensis preparations, in in vitro and in vivo models. None of the 3 metabolites exhibited cytotoxicity within the tested concentration range. In LPS-stimulated RAW 264.7 cells, D-proline and L-iditol significantly reduced the expression of pro-inflammatory cytokines, and in an imiquimod-induced psoriasis-like mouse model, L-iditol significantly reduced disease severity and histopathological scores, whereas the effects of other metabolites were inconsistent. These research results suggest that L-iditol, a candidate metabolite identified in Clonorchis sinensis formulations, exhibits anti-inflammatory effects in both in vitro and in vivo environments and may have therapeutic potential for inflammatory skin diseases such as psoriasis.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: